Effect of nesiritide in patients with acute decompensated heart failure.

CM, O'Connor; RC, Starling; AF, Hernandez; PW, Armstrong; K, Dickstein; V, Hasselblad; GM, Heizer; M, Komajda; BM, Massie; JJ, McMurray; MS, Nieminen; CJ, Reist; JL, Rouleau; K, Swedberg; KF Jr, Adams; SD, Anker; D, Atar; A, Battler; R, Botero; NR, Bohidar; J, Butler; N, Clausell; R, Corbalán; MR, Costanzo; U, Dahlstrom; LI, Deckelbaum; R, Diaz; ME, Dunlap; JA, Ezekowitz; D, Feldman; GM, Felker; GC, Fonarow; D, Gennevois; SS, Gottlieb; JA, Hill; JE, Hollander; JG, Howlett; MP, Hudson; RD, Kociol; H, Krum; A, Laucevicius; WC, Levy; GF, Méndez; M, Metra; S, Mittal; BH, Oh; NL, Pereira; P, Ponikowski; WH, Tang; S, Tanomsup; JR, Teerlink; F, Triposkiadis; RW, Troughton; AA, Voors; DJ, Whellan; F, Zannad; RM, Califf

doi:10.1056/nejmoa1100171

Public

Effect of nesiritide in patients with acute decompensated heart failure.

Shared by NobleBlocks on Jul 1, 2011 • 12:00 AM UTC

Authors:

O'Connor CM

Starling RC

Hernandez AF

Abstract

<h4>Background</h4>Nesiritide is approved in the United States for early relief of dyspnea in patients with acute heart failure. Previous meta-analyses have raised questions regarding renal toxicity and the mortality associated with this agent.<h4>Methods</h4>We randomly assigned 7141 patients who w...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!